https://www.yahoo.com/news/coronavir...153503886.html
No one doubts Norway's success in bringing the pandemic under control. On Friday, there were just 30 people in hospital with coronavirus and five on a ventilator. Only one person had died all week. The per capita death toll is now 44 per million people, just over a tenth of that seen in neighbouring Sweden, where 4,971 people have died.
But this success has come at a prohibitive social and economic cost. An expert committee charged with carrying out a cost-benefit analysis into the lockdown measures in April estimated that they had together cost Norway 27bn kroner (£2.3) every month. With only 0.7 per cent of Norwegians infected, according to NIPH estimates, there is almost no immunity in the population.
The expert committee concluded last Friday that the country should avoid lockdown if there is a second wave of infections.
"We recommend a much lighter approach," the committee's head, Steinar Holden, an Oslo University economics professor, told the Sunday Telegraph. "We should start with measures at an individual level -- which is what we have now -- and if there’s a second wave, we should have measures in the local area where this occurs, and avoid measures at a national level if that is possible."
Norway's current strategy -- using testing, contact tracing, and home isolation to keep the level of infections down without heavy restrictions -- would be best, the report concluded. But if this 'keep down' strategy fails to prevent a surge in cases, a 'brake strategy' which aims to suppress the rate of transmission but not bring it below 1, would be preferable to a lockdown.
"If it’s necessary to have very strict restrictions for a long time, then the costs are higher than letting the infection go through the population," Holden told the Telegraph. "Because that would be immensely costly."
According to the report, a brake strategy would cost as much as 234bn kroner (£20bn) less than an "unstable keep-down" scenario, if you assume that those infected gain immunity and that no vaccine is developed until 2023. But it would also lead to a little over 3,000 additional deaths.